Adial Pharmaceuticals

ADIL

Market cap $5.91M

ADIL Hedge Fund Activity: Q1 2026 in Review

14 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2026, worth a combined $63.6K — down 92% from $778K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADIL and 5 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $63.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $562K sold.

• 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2026, down from 21 in Q4 2025.
• Funds reported $63.6K of Adial Pharmaceuticals stock for Q1 2026, down 92% quarter-over-quarter.
• 5 funds opened new Adial Pharmaceuticals positions in Q1 2026 and 11 closed out, a net change of -6 holders.
• The largest Adial Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $63.4K added.
• The largest Adial Pharmaceuticals seller in Q1 2026 was Armistice Capital, an estimated $562K sold.

Based on aggregated 13F filings for Q1 2026.